ArticleCancer medicine2026
Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority-Serving Hospitals.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmunotherapy has transformed outcomes in stage IV melanoma, yet disparities in access persist. Minority-serving hospitals (MSH) disproportionately care for socioeconomically disadvantaged and minority patients, but their impact on immunotherapy use and survival in melanoma is not well defined.
methodsAdults with stage IV melanoma diagnosed from 2012 to 2020 were identified in the National Cancer Database. MSH were defined as the top decile of institutions by proportion of minority patients with melanoma. Outcomes included immunotherapy receipt and overall survival (OS). Logistic regression assessed predictors of immunotherapy receipt. Cox proportional hazards modeling evaluated OS.
resultsAmong 19,469 patients, 1279 (6.6%) were treated at MSH. MSH patients were more often Hispanic (20.6% vs. 1.4%), from lower-income and less-educated communities, and had Medicaid or no insurance (all p < 0.001). Immunotherapy was less frequently used at MSH (35.7% vs. 44.7%, p < 0.001). On multivariable analysis, treatment at MSH predicted a lower likelihood of immunotherapy receipt (OR 0.70, 95% CI 0.61-0.81, p < 0.001) and worse OS (HR 1.20, 95% CI 1.07-1.36, p = 0.003).
conclusionsStage IV melanoma patients treated at MSH were less likely to receive immunotherapy and had worse survival. These findings highlight institutional disparities beyond patient-level disadvantage and the need for interventions to strengthen access to life-prolonging therapies at MSH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.